illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. Abiomed
Company logo

Abiomed | Sustainability Performance

https://www.abiomed.com
Linkedin

Abiomed, Inc. develops medical devices focused on heart support and recovery, offering technologies that assist in cardiovascular treatment.

1981

United States

1,001 - 5,000 employees

Medical Device

$1B - 10B in revenue

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#8380
Overall
#1818
in United States
#124
in Medical Device

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Arcturus Therapeutics

United States, Hospital & Health Care, Biotechnology


Company logo
NeueHealth

United States, Hospital & Health Care, Hospital & Health Care


Company logo
Envista

United States, Hospital & Health Care, Medical Device

Revenue

1.0B $, 2022▲17.9% YoY

R&D intensity

15.81% 2022

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Abiomed Inc (acquired by Johnson & Johnson 2022 USD 16.6 billion), US medical devices (Impella heart pump major), has faced sustained class actions over the contested 2022 USD 16.6 billion J&J acquisition integration challenges affecting US institutional shareholders, plus periodic US FDA enforcement scrutiny over alleged inadequate Impella heart pump product safety practices affecting US institutional shareholders.
Powered by illuminem

Revenue

1.0B $, FY2022▲17.9% YoY

EBITDA

140.0M $, FY2022▼9.1% YoY

Operating margin

14% Industry: -136▼98.6% YoY

Revenue & EBITDA

$1.0BFY2022 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Revenue by region


Revenue by region %

Europe [Member]
JAPAN
Outside the U.S Member
Rest of world [Member]
UNITED STATES

Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

249.6M 2022▲11.4% YoY

Capex

35.0M 2022▼51.4% YoY

R&D intensity

15.8%FY2022

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

9.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.8

▼ 0.6%

2020

0.8

▲ 1.2%

2021

1.0

▲ 0.2%

2022

1.8

2027

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

67%
Independent Directors

8 out of 12 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Sustainability employees


Total sustainability employees

4-6



    Available in
    Scale package

    Access
  • Email

  • Email